Systematic review with meta-analysis: The effects of rifaximin in hepatic encephalopathy

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 2, 2014, Pages 123-132

  Kimer, N ^a   Krag, A ^b   Moller S ^a   Bendtsen, F ^a   Gluud, L L ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIFAXIMIN;

DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HUMAN; META ANALYSIS; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; UNITED STATES;

BIAS (EPIDEMIOLOGY); HEPATIC ENCEPHALOPATHY; HUMANS; ODDS RATIO; PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMYCINS; SECONDARY PREVENTION;

EID: 84902830462     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12803     Document Type: Review

References (57)

1. Prakash R, Mullen KD,. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25.
2. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H,. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010; 51: 1675-82.
3. Amodio P, Campagna F, Olianas S, et al,. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol 2008; 49: 346-53.
4. Cordoba J,. New assessment of hepatic encephalopathy. J Hepatol 2011; 54: 1030-40.
5. Schliess F, Gorg B, Haussinger D,. Pathogenetic interplay between osmotic and oxidative stress: the hepatic encephalopathy paradigm. Biol Chem 2006; 387: 1363-70.
6. Als-Nielsen B, Gluud LL, Gluud C,. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.
7. Bajaj JS,. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47.
8. Riordan SM, Williams R,. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med 2010; 362: 1140-2.
9. Sharma BC, Sharma P, Agrawal A, Sarin SK,. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009; 137: 885-91.e1.
10. Shawcross DL, Davies NA, Williams R, Jalan R,. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247-54.
11. Sharma P, Sharma BC, Agrawal A, Sarin SK,. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2012; 27: 1329-35.
12. Eltawil KM, Laryea M, Peltekian K, Molinari M,. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012; 18: 767-77.
13. Mullen KD, Dasarathy S,. Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma? J Hepatol 2004; 41: 147-8.
14. Gluud LL, Dam G, Borre M, et al,. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr 2013; 143: 1263-8.
15. Bass NM, Mullen KD, Sanyal A, et al,. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
16. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L,. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008; 20: 1064-70.
17. Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY,. Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract 2013; 2013: 236963.
18. Higgins JT, Green S,. Cochrane handbook for systematic reviews of interventions, March 2011. Available at: http://handbook.cochrane.org. Accessed February 2014.
19. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
20. Ali B, Zaidi YA, Alam A, Anjum HS,. Efficacy of rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver. J Coll Physicians Surg Pak 2014; 24: 269-73.
21. Bajaj JS, Heuman DM, Wade JB, et al,. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-487.e1.
22. Bass NM, Ahmed A, Johnson L, Gardner JD,. Rifaximin treatment is beneficial for mild hepatic encephalopathy. Hepatology 2004; 40: 646A.
23. Bucci L, Palmieri GC,. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 109-18.
24. De Marco F, Santamaria Amoto P, D'arienzo A,. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Current Ther Res 1984; 36: 668-74.
25. Fera G, Fransesco A, Nigro M, Schiraldi O, Ferrieri A,. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 57-66.
26. Festi D, Mazella G, Orsini M, Sottili S, Sangermano A, Li Bassi S,. Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. Curr Ther Res 1993; 54: 598-609.
27. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C,. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003; 49: 53-62.
28. Mas A, Rodes J, Sunyer L, et al,. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-8.
29. Massa P, Vallerino F, Dodero M,. Treatment of hepatic encephalopathy with rifaximin. Eur J Clin Res 1993; 4: 7-18.
30. Miglio F, Valpiani D, Rossellini SR, Ferrieri A,. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997; 13: 593-601.
31. Paik YH, Lee KS, Han KH, et al,. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46: 399-407.
32. Parini P, Cipolla A, Ronchi M, Salzetta A, Mazella G, Roda E,. Effect of rifaximin and paromycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992; 52: 34-9.
33. Pedretti G, Calzetti C, Missale G, Fiaccadori F,. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991; 23: 175-8.
34. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK,. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108: 1458-63.
35. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK,. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-16.
36. Song KH, Lee K, Kim MH, et al,. The clinical efficacy of rifaximin in the treatment of hepatic encephalopaty (comparison with lactulose). Hepatology 2000; 32: 407A.
37. Testa R, Eftimiadi C, Sukkar GS, et al,. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985; 11: 387-92.
38. Dimick-Santos L,. Meeting of The Gastrointestinal Drugs Advisory Committe (GIDAC) to evaluate Rifaximin 550 mg tablets for the proposed indication of maintenance of remission of Hepatic Encephalopathy (HE) in patients 18 years old and older. NDA 22-554 Clinical Review: FDA; 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM201079.pdf. Accessed February 2014.
39. Salix Pharmaceuticals Inc. Xifaxan (rifaximin) tablets 550 mg for hepatic encephalopathy. Committee USFaDAGDA, 2010. Available at: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ GastrointestinalDrugs AdvisoryCommittee/UCM203248.pdf. Accessed February 2014.
40. Salix Pharmaceuticals Inc. Xifaxan (rifaximin) tablets, 550 mg NDA 22-554. Briefing document for the Gastrointestinal Drugs Advisory Committee Meeting 23 February 2010, FDA; 2010. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ GastrointestinalDrugsAdvisoryCommittee/UCM201081.pdf. Accessed February 2014.
41. Regina Alivisatos EC. 21-361 Xifaxan Medical Review Part 6 Access Data FDA. Salix Pharmaceuticals, FDA, 2002. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/nda/2004/21-361-Xifaxan-Medr-P6.pdf. Accessed February 2014.
42. Sanyal A, Younossi ZM, Bass NM, et al,. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011; 34: 853-61.
43. Riggio O, Masini A, Efrati C, et al,. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42: 674-9.
44. Savovic J, Jones H, Altman D, et al,. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012; 16: 1-82.
45. Mullen KD, Prakash RK,. New perspectives in hepatic encephalopathy. Clin Liver Dis 2012; 16: 1-5.
46. Bajaj JS, Cordoba J, Mullen KD, et al,. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011; 33: 739-47.
47. Randolph C, Hilsabeck R, Kato A, et al,. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009; 29: 629-35.
48. Morgan MY, Morris RW,. Rifaximin for the treatment of hepatic encephalopathy; a meta-analysis of randomised studies. Gut 2012; 61 (Suppl. 2): A203-4.
49. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A,. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002; 66: 246-56.
50. Kalambokis GN, Mouzaki A, Rodi M, et al,. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012; 10: 815-8.
51. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD,. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-5.
52. Danulescu RM, Ciobica A, Stanciu C, Trifan A,. The role of rifaximine in the prevention of the spontaneous bacterial peritonitis. Rev Med Chir Soc Med Nat Iasi 2013; 117: 315-20.
53. Huang E, Esrailian E, Spiegel BM,. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy-a decision analysis. Aliment Pharmacol Ther 2007; 26: 1147-61.
54. Kimer N, Krag A, Gluud LL,. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence 2014; 8: 331-8.
55. Leevy CB, Phillips JA,. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007; 52: 737-41.
56. Neff G,. Pharmacoeconomics of hepatic encephalopathy. Pharmacotherapy 2010; 30: 28S-32S.
57. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM,. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012; 55: 1164-71.